HENLIUS Shares Surge Over 5% on IND Approval for Proprietary HLX97 Inhibitor

Stock News03-06

HENLIUS (02696) saw its shares rise more than 5%. At the time of writing, the stock was up 5.02%, trading at HK$68, with a turnover of HK$19.48 million. The increase follows an announcement on March 5 that the company’s self-developed HLX97, a small molecule inhibitor targeting KAT6A/B, has received Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA) for a Phase 1 clinical trial in patients with advanced or metastatic solid tumors. HLX97 is designed to treat advanced or metastatic solid tumors by inhibiting the activity of lysine acetyltransferases KAT6A and KAT6B. Non-clinical studies have demonstrated that HLX97 exhibits promising anti-tumor efficacy and a favorable safety profile. As of the announcement date, no KAT6A/B small molecule inhibitors have been approved for marketing anywhere in the world.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment